Mackenzie Financial Corp Sells 3,792 Shares of Shire PLC (SHPG)
Mackenzie Financial Corp cut its holdings in shares of Shire PLC (NASDAQ:SHPG) by 59.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,596 shares of the biopharmaceutical company’s stock after selling 3,792 shares during the period. Mackenzie Financial Corp’s holdings in Shire were worth $403,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Harding Loevner LP lifted its stake in Shire by 18,894.4% during the third quarter. Harding Loevner LP now owns 127,537,052 shares of the biopharmaceutical company’s stock worth $20,354,000 after purchasing an additional 126,865,607 shares during the last quarter. Boston Partners lifted its stake in Shire by 60.9% during the fourth quarter. Boston Partners now owns 2,342,391 shares of the biopharmaceutical company’s stock worth $363,351,000 after purchasing an additional 886,572 shares during the last quarter. Janus Henderson Group PLC lifted its stake in Shire by 35.3% during the third quarter. Janus Henderson Group PLC now owns 1,740,973 shares of the biopharmaceutical company’s stock worth $266,613,000 after purchasing an additional 454,092 shares during the last quarter. Ameriprise Financial Inc. lifted its stake in Shire by 6.4% during the third quarter. Ameriprise Financial Inc. now owns 1,606,342 shares of the biopharmaceutical company’s stock worth $245,997,000 after purchasing an additional 96,115 shares during the last quarter. Finally, Third Point LLC bought a new stake in Shire during the third quarter worth $183,768,000. Hedge funds and other institutional investors own 19.75% of the company’s stock.
Several equities research analysts have weighed in on SHPG shares. Zacks Investment Research cut Shire from a “hold” rating to a “sell” rating in a research note on Tuesday, January 2nd. Bank of America upped their target price on Shire from $236.00 to $237.00 and gave the stock a “buy” rating in a research note on Monday, February 5th. Royal Bank of Canada restated a “buy” rating on shares of Shire in a research note on Thursday, November 16th. Cantor Fitzgerald set a $222.00 target price on Shire and gave the stock a “buy” rating in a research note on Thursday, November 16th. Finally, Cowen set a $225.00 target price on Shire and gave the stock a “buy” rating in a research note on Friday, January 5th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and twelve have given a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $204.00.
Shire (NASDAQ:SHPG) last posted its quarterly earnings data on Wednesday, February 14th. The biopharmaceutical company reported $3.98 earnings per share for the quarter, beating the Zacks’ consensus estimate of $3.86 by $0.12. The business had revenue of $4.14 billion during the quarter. Shire had a return on equity of 14.19% and a net margin of 28.17%. The business’s revenue for the quarter was up 8.9% on a year-over-year basis. During the same quarter in the previous year, the company earned $3.37 earnings per share. research analysts predict that Shire PLC will post 15.23 EPS for the current fiscal year.
The business also recently disclosed a semiannual dividend, which will be paid on Tuesday, April 24th. Investors of record on Friday, March 9th will be issued a $0.8937 dividend. This represents a yield of 1.33%. This is an increase from Shire’s previous semiannual dividend of $0.15. The ex-dividend date is Thursday, March 8th. Shire’s dividend payout ratio is presently 17.30%.
TRADEMARK VIOLATION NOTICE: “Mackenzie Financial Corp Sells 3,792 Shares of Shire PLC (SHPG)” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright laws. The original version of this piece can be accessed at https://www.thecerbatgem.com/2018/03/14/mackenzie-financial-corp-sells-3792-shares-of-shire-plc-shpg.html.
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Want to see what other hedge funds are holding SHPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shire PLC (NASDAQ:SHPG).
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.